Results 181 to 190 of about 1,317,896 (291)

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Correction: Perceptions and practices of community pharmacists towards the use of short-acting beta-2 agonists inhalers in Malaysia: A cross-sectional survey. [PDF]

PLoS One
Loh ZC, Hussain R, Ababneh BF, Muneswarao J, Ong SC, Ur-Rehman A, Babar ZU.   +6 more
europepmc   +1 more source

The Number of partons effective in the beta decay of the nucleon

, 1993
D. H. Wilkinson
openalex   +1 more source

Using Nonnatural Amino Acids to Control Metal-Coordination Number in Three-Stranded Coiled Coils V.L.P. thanks the National Institutes of Health for support of this research (ES012236), C.C. thanks the Chemistry/Biology Interface Training Program for a Fellowship (TG32 GM008597), and L.H. thanks the EU for support within the network on “Metallo-beta-lactamases as model zinc enzymes”.

, 2006
Kyunghoon Lee, Chris Cabello, Lars Hemmingsen, E. Neil G. Marsh, Vincent L. Pecoraro   +4 more
openalex   +2 more sources

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Evaluating Methods for High-Dimensional Mediation in Metabolomics Data. [PDF]

Environ Sci Technol
Hoffman SS, Liang D, Dunlop A, Everson T, Gaskins AJ, Jones DP, Hüls A, Marcus M, Naimi AI.   +8 more
europepmc   +1 more source

On the Statistical Properties of Tests of Parameter Restrictions in Beta-pricing Models With a Large Number of Assets

Amedeo Andriollo, Cesare Robotti, Giulio Rossetti   +2 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source